Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | May 10, 2017 | May 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date May 10, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Buy Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $12.30 · Expires 2027-05-10 | Direct | 23,600 |
Reported balance
After 2017-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-10 · Grant · Acquired 23,600 · Balance 23,600 F1: Options to buy 23,600 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the date of the Company's 2018 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to buy 23,600 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the date of the Company's 2018 annual general meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2017 Filed May 12, 2017 16:48 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 23,600 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001209191-17-032014 · doc4.xml · derivative · entry 1 Perlhagen Gert L. · CIK 0001654361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,600 Underlying: Ordinary Shares · 23,600 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options to buy 23,600 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the date of the Company's 2018 annual general meeting of shareholders. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:06 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 125,000 | $6.93 | $866,250.00 |
DisclosureSEC source: 0000899243-17-007750 · doc4.xml · nonDerivative · entry 1 Perlhagen Gert L. · CIK 0001654361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,125,000 F1 · price: On March 14, 2017, Mr. Perlhagen purchased 125,000 shares in multiple trades at prices ranging from $6.825 to $7.05. The price reported above reflects the weighted average purchase price. Mr. Perlhagen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 09:05 UTC | NovoCure Ltd NVCR · Entity 4494 | OtherOrdinary Shares | 6,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-17-000594 · edgar.xml · nonDerivative · entry 1 Perlhagen Gert L. · CIK 0001654361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000,000 F1 · kind: Distribution from the Oden Trust to Mr. Perlhagen. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.